Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Enterprise Value (2019 - 2025)

Historic Enterprise Value for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to -$1.1 billion.

  • Madrigal Pharmaceuticals' Enterprise Value fell 1112.75% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 1112.75%. This contributed to the annual value of -$926.3 million for FY2024, which is 4606.62% down from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Enterprise Value of -$1.1 billion as of Q3 2025, which was down 1112.75% from -$797.0 million recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Enterprise Value peaked at -$153.2 million during Q3 2022, and registered a low of -$1.1 billion during Q3 2025.
  • Moreover, its 5-year median value for Enterprise Value was -$329.5 million (2023), whereas its average is -$549.0 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first surged by 4878.99% in 2022, then crashed by 32979.24% in 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' Enterprise Value (Quarter) stood at -$270.3 million in 2021, then crashed by 32.71% to -$358.8 million in 2022, then crashed by 76.75% to -$634.1 million in 2023, then tumbled by 46.07% to -$926.3 million in 2024, then dropped by 19.81% to -$1.1 billion in 2025.
  • Its Enterprise Value stands at -$1.1 billion for Q3 2025, versus -$797.0 million for Q2 2025 and -$843.1 million for Q1 2025.